Jeff Yass’s Innate Pharma IPHA Stock Holding History

Jeff Yass’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,315	Closed	-$37.8K	–	12593
2023 Q1	$37.8K	Hold	13,315	–	–	﹤0.01%	11819
2022 Q4	$49.7K	Buy	+13,315	New	+$30.3K	﹤0.01%	11402

Other funds holding IPHA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jeff Yass's IPHA Position: Q2 2023 in Review

Jeff Yass sold out of Innate Pharma (IPHA) in Q2 2023, closing a stake of 13,315 shares — an estimated $37.8K sold.

Jeff Yass first reported a position in IPHA in Q4 2022 and held it in 2 quarters. The position peaked at $49.7K in Q4 2022. 9 funds tracked by Wall St. Rank hold IPHA as of Q2 2023.

Jeff Yass reported no remaining Innate Pharma position as of Q2 2023 after selling out during the quarter.
Jeff Yass sold 13,315 Innate Pharma shares in Q2 2023, an estimated $37.8K.
Jeff Yass first reported a position in Innate Pharma in Q4 2022 and held it in 2 quarters.
Jeff Yass's Innate Pharma position peaked at $49.7K in Q4 2022.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.